Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 12 July 2012 | By Alexander Gaffney, RAC
Canadian health regulators have released a detailed breakdown of all adverse event reports submitted to Health Canada in 2011, providing a number of interesting insights and trends.
Health Canada said it had received 41,923 domestic adverse event reports (AERs), of which 78% were classified as "serious" adverse events. The overwhelming majority of these cases concerned pharmaceutical products (27,602) and biotechnology products (12,419). The remaining products-blood products, biologics, natural health products, radiopharmaceuticals, cells, tissues and organs-combined accounted for 1,902 of the adverse events.
Nearly a quarter of all AERs came from immunosuppressant drugs-more than the next four drug classes (psycholeptics, drugs for treatment of bone diseases, psychoanaleptics and antineoplastic agents) combined. Analgesics, antibacterials, antithrombotic agencts and agents acting on the renin-angiotensis system were all significant contributors to AERs as well.
The majority of reports originated from the marketing authorization holder (82%), while 15.4% came from consumers, patients and non-hospital-based healthcare professionals. A remaining 2.6% of cases came from hospitals.
Medical device AERs are compiled separately by Health Canada. The agency indicated it received 9,228 medical device AERs in 2011, but declined to make a similar breakdown of its data available.
The number of adverse events reported to Health Canada was up significantly over 2010-a trend consistent with past years. In 2001, the agency received just over 10,000 adverse event reports each year. As of 2006, that number had increased to nearly 15,000, and subsequently increased dramatically to nearly 20,000 in 2008 and 35,000 in 2010.
Read more:
Health Canada - Canadian Adverse Reaction Newsletter, Volume 22 - Issue 3 - July 2012
Tags: Serious Adverse Events, Adverse Event Reports, Trends, AERS, Adverse Events, Latest News, data
Regulatory Focus newsletters
All the biggest regulatory news and happenings.